In spite of promising results with GLP-1R agonists in preclinical studies of DR [219], hopes for improvements in the treatment of the condition were initially tempered by early trials that showed worsening of retinopathy in a significant number of patients [212,220]. This evidence concerns the gene GLP1R and retinal disorder.